Liraglutide for the treatment of obesity

Elmien Bronkhorst*, Natalie Schellack

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare intervention in this patient population, the use of adjunctive pharmacotherapeutic agents is often required. This article provides an overview of the first injectable treatment option, namely liraglutide, in the management of obesity, or of patients that are overweight in the presence of significant co-morbid conditions.

Original languageEnglish
Pages (from-to)38-40
Number of pages3
JournalSouth African Family Practice
Issue number3
Publication statusPublished - 1 May 2016


  • GLP-1
  • Incretin
  • Liraglutide
  • Obesity
  • Overweight
  • Type 2 diabetes mellitus
  • Weight-loss


Dive into the research topics of 'Liraglutide for the treatment of obesity'. Together they form a unique fingerprint.

Cite this